(S)-1-(4-chlorophenyl)-3-(1-(5-(2-hydroxyethyl)-1,2,4-oxadiazol-3-yl)-2-(4-methoxyphenyl)ethyl)urea

ID: ALA5281870

Max Phase: Preclinical

Molecular Formula: C20H21ClN4O4

Molecular Weight: 416.87

Names and Identifiers

Canonical SMILES:  COc1ccc(C[C@H](NC(=O)Nc2ccc(Cl)cc2)c2noc(CCO)n2)cc1

Standard InChI:  InChI=1S/C20H21ClN4O4/c1-28-16-8-2-13(3-9-16)12-17(19-24-18(10-11-26)29-25-19)23-20(27)22-15-6-4-14(21)5-7-15/h2-9,17,26H,10-12H2,1H3,(H2,22,23,27)/t17-/m0/s1

Standard InChI Key:  WQKNMFDTDNNOOC-KRWDZBQOSA-N

Molfile:  

 
     RDKit          2D

 29 31  0  0  0  0  0  0  0  0999 V2000
    2.8480   -1.9602    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1335   -1.5476    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1335   -0.7261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8435   -0.3173    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5551   -0.7281    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5551   -1.5456    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2665   -0.3174    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.2665    0.5040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4221   -1.9584    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7106   -1.5476    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7106   -0.7262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0464   -0.2436    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3001    0.5373    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.1212    0.5373    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3749   -0.2436    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.5319    1.2487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3535    1.2487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7642    1.9602    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0007   -1.9584    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7121   -1.5476    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7121   -0.7262    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -1.4236   -1.9584    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1350   -1.5476    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8419   -1.9576    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5551   -1.5513    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5551   -0.7266    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8437   -0.3162    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1350   -0.7262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2665   -0.3158    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  2  0
  4  3  1  0
  5  4  2  0
  1  6  2  0
  6  5  1  0
  5  7  1  0
  7  8  1  0
  9  2  1  0
 10  9  1  0
 10 11  1  6
 12 11  2  0
 12 13  1  0
 13 14  1  0
 14 15  2  0
 15 11  1  0
 14 16  1  0
 16 17  1  0
 17 18  1  0
 19 10  1  0
 20 19  1  0
 20 21  2  0
 22 20  1  0
 23 22  1  0
 24 23  1  0
 25 24  2  0
 26 25  1  0
 27 26  2  0
 23 28  2  0
 28 27  1  0
 26 29  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5281870

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 416.87

Molecular Weight (Monoisotopic): 416.1251

AlogP: 3.37

#Rotatable Bonds: 8

Polar Surface Area: 109.51

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.46

CX Basic pKa: ┄

CX LogP: 3.42

CX LogD: 3.42

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.52

Np Likeness Score: -1.57

References

1. Maciuszek M, Cacace A, Brennan E, Godson C, Chapman TM..  (2021)  Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.,  213  [PMID:33486199] [10.1016/j.ejmech.2021.113167]

Source

Source(1):

• Scientific Literature